More on the GLP1-Lithium Interaction

When 7-Up was introduced as a lithiated beverage in the 1970’s, it was advertised for weight loss. That claim hasn’t held up, but new studies show no statistically detectable weight gain with lithium.

Experts explain how to manage the potential interaction

STUDY: Cotrik E et al, International Clinical Psychopharmacology 2026 

STUDY TYPE: Review/expert perspective

FUNDING: Independent

Background

More than half of adults with bipolar disorder carry excess weight, and recent reports suggest GLP-1 meds can raise lithium levels, particularly semaglutide. In June 2026, European regulators started tracking this interaction.

The Study

• The authors reviewed six published cases of lithium toxicity or elevated levels tied to starting, switching, or increasing a GLP-1 drug.
• They sorted the evidence into three tiers: the raw case reports, the biological mechanisms that might explain them, and a speculative theory about timing.
• They tested each proposed mechanism against the pharmacology literature.

Results

One possible mechanism is dehydration, as patients eat and drink less on GLP-1 agonists.

However, one well-documented case showed a lasting rise in lithium level per milligram of dose, persisting for months without any nausea, vomiting, or reduced intake. Weight loss lowers lithium clearance, but the math only accounts for about a quarter of that shift.

What about delayed stomach emptying? This is often blamed, but the authors found it unlikely. Pharmacokinetic data show it changes the timing of absorption, not the total amount absorbed.

Practice Implications

1. When you start or increase a GLP-1 drug in a patient on lithium, check a lithium level about a week later and again after any dose change, using the same timing and formulation each time.
2. Ask about appetite and fluid intake at that visit, since reduced intake is the likely driver of sudden spikes.
3. If a patient stops the GLP-1 agonist after lowering their lithium dose, recheck the level, since they may now be underdosed.
4. There’s no reason to avoid lithium in these patients or lower the dose preemptively, as this is an emerging and rare signal, not a settled interaction.